LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Fechado

SetorSaúde

2.63 -5.73

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.6

Máximo

2.66

Indicadores-chave
By Trading Economics
Rendimento	22M 9.7M
Vendas	586K 718K
Margem de lucro	1,345.822
Funcionários	23
EBITDA	-152K -12M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+90.36% upside

Dividendos
By Dow Jones
Próximos Ganhos	19 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	344M 483M
Abertura anterior	8.36
Fecho anterior	2.63

Sentimento de Notícias

By Acuity

50%

155 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.275 / 0.33 Suporte e Resistência

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 de mai. de 2026, 16:02 UTC

Ganhos

Grandes Movimentos do Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 de mai. de 2026, 14:55 UTC

Grandes Movimentos do Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 de mai. de 2026, 14:43 UTC

Grandes Movimentos do Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 de mai. de 2026, 17:28 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 de mai. de 2026, 16:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 de mai. de 2026, 15:20 UTC

Ganhos

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 de mai. de 2026, 14:33 UTC

Conversa de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

90.36% parte superior

Previsão para 12 meses

Média 5.33 USD 90.36%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimento

By Acuity

155 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.